Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.43 |
-0.54 |
-0.11 |
-25.58% |
2024-03-21 |
2023-12 |
-1.11 |
N/A |
N/A |
N/A |
2024-03-21 |
2023-12 |
-1.11 |
-0.71 |
0.4 |
36.04% |
2023-11-09 |
2023-09 |
-0.51 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.51 |
-3.78 |
-3.27 |
-641.18% |
Date |
Firm |
Action |
From |
To |
2023-09-27 |
Raymond James |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2022-11-29 |
BEETHAM THOMAS W |
Officer |
19.90K |
Stock Award(Grant) |
2022-11-29 |
DEARDORF CAREN |
Officer |
19.76K |
Stock Award(Grant) |
2024-01-21 |
FAIRMOUNT FUNDS MANAGEMENT LLC |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Stock Award(Grant) |
2022-11-29 |
GARDNER JASON M PH.D. |
Chief Executive Officer |
944.95K |
Stock Award(Grant) |
2022-11-29 |
MAHONEY STEPHEN F |
Chief Operating Officer |
17.26K |
Stock Award(Grant) |
2024-01-21 |
MENG LEI |
Director |
0.00 |
Stock Award(Grant) |